Huang Xinrui, Lv Xin, Song Hui, Yang Qing, Sun Yuemin, Zhang Wenjuan, Yu Xiangdong, Dong Shaozhuang, Yao Wei, Li Yongle, Wang Qing, Wang Bei, Ma Liya, Huang Guowei, Gao Yuxia
Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, China.
Department of Nutrition and Food Science, School of Public Health, Tianjin Medical University, Tianjin, China.
Clin Chim Acta. 2017 Aug;471:314-320. doi: 10.1016/j.cca.2017.07.001. Epub 2017 Jul 4.
The role of homocysteine (Hcy) in the pathogenesis of coronary artery disease (CAD) is controversial, as decreased Hcy levels have not demonstrated consistent clinical benefits. Recent studies propose that S-adenosylhomocysteine (SAH), and not Hcy, plays a role in cardiovascular disease (CVD). We aimed to assess the relationship between plasma SAH and coronary artery lesions. Participants (n=160; aged 40-80years) with chest pain and suspected CAD underwent coronary angiography (CAG) for assessment of coronary artery stenosis, and were assigned to either the atherosclerosis (AS) or CAD group. Plasma SAH and S-adenosylmethionine (SAM) concentrations were measured and the association between coronary artery lesions and SAH was assessed. SAH levels were significantly higher in the CAD group (23.09±2.4nmol/L) than in the AS group (19.2±1.5nmol/L). While the AS group had higher values for SAM/SAH (5.1±0.7 vs. 4.1±1.1), levels of SAM, Hcy, folate, and vitamin B12 were similar in the two groups. Coronary artery lesions were associated with SAH (β=11.8 [95% CI: 5.88, 17.7, P<0.05]. Plasma SAH concentrations are independently associated with coronary artery lesions among patients undergoing coronary angiography. Plasma SAH might be a novel biomarker for the early clinical identification of CVD.
同型半胱氨酸(Hcy)在冠状动脉疾病(CAD)发病机制中的作用存在争议,因为降低Hcy水平并未显示出一致的临床益处。最近的研究表明,在心血管疾病(CVD)中起作用的是S-腺苷同型半胱氨酸(SAH),而非Hcy。我们旨在评估血浆SAH与冠状动脉病变之间的关系。对160名年龄在40 - 80岁、有胸痛且疑似CAD的参与者进行冠状动脉造影(CAG)以评估冠状动脉狭窄情况,并将其分为动脉粥样硬化(AS)组或CAD组。测量血浆SAH和S-腺苷甲硫氨酸(SAM)浓度,并评估冠状动脉病变与SAH之间的关联。CAD组的SAH水平(23.09±2.4nmol/L)显著高于AS组(19.2±1.5nmol/L)。虽然AS组的SAM/SAH值较高(5.1±0.7对4.1±1.1),但两组的SAM、Hcy、叶酸和维生素B12水平相似。冠状动脉病变与SAH相关(β=11.8 [95% CI:5.88, 17.7, P<0.05])。在接受冠状动脉造影的患者中,血浆SAH浓度与冠状动脉病变独立相关。血浆SAH可能是CVD早期临床识别的一种新型生物标志物。